Acella Recalls Superpotent NP Thyroid 15 Thyroid Tablets Nationwide
Acella Pharmaceuticals is voluntarily recalling 49,128 bottles of NP Thyroid 15 tablets because they are superpotent. The FDA classified this as a Class I recall.
What this means for you
Highest-severity recall. Risk of serious injury or death is documented or strongly suspected. Stop using the product now and follow the agency's instructions.
Our severity reasoning: The FDA classified this recall as Class I, which meets the rubric criteria for a Critical severity score (5).
Plain-English summary
Acella Pharmaceuticals, LLC is voluntarily recalling 49,128 bottles of NP Thyroid 15 (Levothyroxine, Liothyronine) tablets. The product is a prescription-only thyroid medication manufactured in Alpharetta, Georgia, and distributed nationwide in the United States and Puerto Rico. The specific lots affected are M331G18-1, M331J18-1, M331J18-2, M331M18-1, and M331M18-2, with expiration dates ranging from June 2020 to November 2020.
The reason for the recall is that the drug is superpotent, meaning it contains a higher concentration of the active ingredient than intended. The FDA has classified this recall as Class I, which indicates a reasonable probability that use of the product will cause serious adverse health consequences or death. The recall was initiated by the firm on May 22, 2020, and was terminated on January 19, 2022.
Patients who have been prescribed this medication should contact their healthcare provider for guidance on alternative treatments or further instructions. Consumers should check their medication bottles for the specific lot numbers and expiration dates listed above to determine if they are affected.
The recalled product
- Product
- NP THYROID 15 (LEVOTHYROXINE, LIOTHYRONINE)
- Brand
- NP THYROID 15
- Manufacturer
- Acella Pharmaceuticals, LLC
- Category
- Drug — Thyroid Medication
- Hazard
- Affected units
- 49,128
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lots: M331G18-1 Exp. JUN-2020
- M331J18-1
- M331J18-2
- Exp. AUG-2020
- M331M18-1
- M331M18-2 Exp. NOV-2020
UPCs (4)
- 0342192329102
- 0342192330108
- 0342192327016
- 0342192328013
Distribution
Part of a larger recall action
This product is one of 3 recalled by Acella Pharmaceuticals, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same brand · NP THYROID 15
- CriticalAcella Recalls Subpotent NP Thyroid 15 Tablets Nationwide
FDA (Drugs) · 2021-06-02
- CriticalAcella Recalls Subpotent NP Thyroid 15 Prescription Tablets
FDA (Drugs) · 2021-06-02
- CriticalAcella Pharmaceuticals Recalls Subpotent NP Thyroid 15 Prescription Tablets
FDA (Drugs) · 2021-06-02
- CriticalAcella Recalls Subpotent NP Thyroid 15 Tablets Nationwide
FDA (Drugs) · 2021-06-02
- SevereAcella Recalls Subpotent NP Thyroid 15 Tablets Nationwide
FDA (Drugs) · 2021-06-02
Same manufacturer · Acella Pharmaceuticals, LLC
See all →- SevereNaproxen Oral Suspension Recalled for Lead and Lithium Contamination
FDA (Drugs) · 2026-05-13
- ModerateDoxycycline hyclate tablets recalled after stability testing failed dissolution specifications
FDA (Drugs) · 2025-10-15
- ModeratePrescription skin cleanser recalled nationwide due to subpotency
FDA (Drugs) · 2024-05-15
- ModerateAcella Recalls Sodium Sulfacetamide Cleansing Pads for Subpotency
FDA (Drugs) · 2022-12-07
- LowPhenytoin Sodium Injection Recalled for Missing Barcode on Vial Label
FDA (Drugs) · 2022-11-30
Same hazard · superpotent drug
See all →- HighLevothyroxine Sodium Tablets Recalled Due to Potency Failures
FDA (Drugs) · 2024-12-18
- SevereLupin Recalls Cefprozil Oral Suspension Due to Superpotent Drug Concerns
FDA (Drugs) · 2021-04-21
- ModerateRocky Mountain Sunscreen Lip Balm Recalled for Excess Octisalate
FDA (Drugs) · 2020-09-02
- CriticalFerring Recalls DDAVP Nasal Spray Due to Superpotent Drug Risk
FDA (Drugs) · 2020-08-26
- CriticalFerring Recalls STIMATE Nasal Spray Due to Superpotent Drug Risk
FDA (Drugs) · 2020-08-26